Order of colon versus liver removal during simultaneous surgery for colorectal cancer with liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational analysis comparing outcomes by resection order in patients who underwent simultaneous colon and liver removal for colorectal cancer with synchronous liver metastases. Participating cases come from a single surgical center and include minimally invasive and open approaches, with exclusion of emergency resections, extrahepatic disease, and high surgical-risk patients (ASA > 3). Key outcomes include intraoperative blood loss, postoperative complications including anastomotic healing, length of stay, and time to chemotherapy, with at least six months of follow-up required. The study aims to clarify whether resection order affects perioperative results when minor hepatectomies are paired with standard colon resections.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients diagnosed with colorectal cancer with synchronous liver metastases during the reference period, who underwent simultaneous resection.

Exclusion Criteria:

* Simultaneous emergency resection due to symptoms of the primary tumor.
* Presence of extrahepatic metastatic disease confirmed at the time of resection or diagnosis.
* High surgical risk defined as an ASA risk score greater than 3.
* At least 10 cases performed by the invited center during the study period.
* Incomplete data or follow-up of less than 6 months.

Where it's running

• SC Chirurgia Generale
  Alessandria, Piedmont, Italy Recruiting

Study contacts

• Study coordinator: Clinical Trial Center
• Email: clinicaltrialcenter@ospedale.al.it
• Phone: 0131206893

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Surgery for liver metastases in patients with RAS-mutated colorectal cancer

  This study is testing if a specific type of liver surgery can help people with RAS-mutated colorectal cancer live longer and healthier after their treatment compared to a different type of surgery.

  Recruiting at 36 sites Technische Universität Dresden · Mannheim, Baden-Wurttemberg and 36 other locations · NCT04678583

• AI model to predict risk of liver spread after colorectal cancer surgery

  This project will test whether an AI model using preoperative CT scans, postoperative pathology images, and routine clinical data can predict the risk of liver metastasis within two years for people having curative surgery for stage I–III colorectal cancer.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07392567

• Multimodal Thermal Therapy for Malignant Liver Tumors

  This study tests a combined cryo- and heat-based therapy to see if it can help people with liver cancers live longer and have fewer tumors.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07159048

• Fecal transplant plus QL1706, bevacizumab, and XELOX as first-line treatment for advanced MSS colon cancer with liver metastases

  This trial will test whether giving a fecal microbiota transplant before combined QL1706, bevacizumab, and XELOX chemotherapy helps adults with untreated advanced MSS colon cancer that has spread to the liver.

  Recruiting Phase 2 Changzhou No.2 People's Hospital · Changzhou · NCT06801665

• PULSAR combined with PD-1 antibody, chemotherapy, and bevacizumab for colorectal cancer that has spread to the liver

  This trial tests if adding PULSAR radiotherapy to a regimen with a PD-1 blocker, standard chemotherapy, and bevacizumab helps people with colorectal cancer liver metastases live longer without their disease getting worse.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT06788171

• Treatment for colorectal cancer liver metastasis using combined therapies

  This study is testing a new treatment combining a special procedure and medication for people with colorectal cancer that has spread to the liver and hasn't responded to earlier treatments.

  Recruiting Phase 2 Shanghai 6th People's Hospital · Shanghai · NCT06590259

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.